2 days Ago By Defense World Staff
KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 7,300 shares of the biopharmaceutical company’s stock, valued at approximately $69,000.
Several other hedge funds also recently made changes to their positions in TBPH. Barclays PLC lifted its stake in Theravance Biopharma by 279.9% during the third quarter.
Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 48,316 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Theravance Biopharma during the third quarter worth $251,000. Magnetar Financial LLC lifted its position in shares of Theravance Biopharma by 125.
8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 15,328 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the 4th quarter valued at about $103,000.
Finally, American Century Companies Inc. grew its position in shares of Theravance Biopharma by 11.9% during the 4th quarter.
American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company’s stock valued at $733,000 after buying an additional 8,289 shares during the last quarter. Institutional investors and hedge funds own 99.
10% of the company’s stock. Insider Transactions at Theravance BiopharmaIn related news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.
00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085.
This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Insiders own 6.90% of the company’s stock. Analyst Ratings ChangesSeparately, HC Wainwright reissued a “buy” rating and issued a $15.
00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.
com, the company currently has a consensus rating of “Hold” and an average price target of $13.75.View Our Latest Stock Analysis on Theravance BiopharmaTheravance Biopharma Stock PerformanceTBPH stock opened at $8.
40 on Friday. The stock’s fifty day moving average is $9.18 and its two-hundred day moving average is $9.
13. The stock has a market capitalization of $415.56 million, a price-to-earnings ratio of -8.
32 and a beta of 0.14. Theravance Biopharma, Inc.
has a 1 year low of $7.44 and a 1 year high of $10.90.
Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.
05) by ($0.26). Theravance Biopharma had a negative net margin of 78.
18% and a negative return on equity of 24.79%. The firm had revenue of $18.
75 million during the quarter, compared to the consensus estimate of $29.90 million. As a group, analysts predict that Theravance Biopharma, Inc.
will post -1.09 EPS for the current fiscal year. About Theravance Biopharma (Free Report)Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines.
Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See AlsoFive stocks we like better than Theravance BiopharmaInsider Trades May Not Tell You What You ThinkJPMorgan is a Buy, if You Can Handle The Volatility Best Stocks Under $5.00United States Steel’s Crash: An Unmissable Buying OpportunityHigh Flyers: 3 Natural Gas Stocks for March 2022Rocket Lab Stock: Weathering the Storm, Time for a Comeback?.
